Effect of cetuximab plus FOLFOX4 regimen on clinical outcomes in advanced gastric carcinoma patients receiving evidence-based care

Figure 1 Effect of cetuximab + FOLFOX4 regimen on serum tumor markers in advanced gastric carcinoma patients receiving evidence-based care. A: The research group had significantly reduced carbohydrate antigen 19-9 (CA19-9) levels after treatment, which was lower compared with the pre-treatment levels and the control group; B: The research group had significantly reduced CA72-4 levels after treatment, which was lower compared with the pre-treatment levels and the control group; C: The research group had significantly reduced carcinoembryonic antigen levels after treatment, which was lower compared with the pre-treatment levels and the control group. ^aP < 0.05 and ^bP < 0.01, respectively. FOLFOX4 consists of oxaliplatin, folinic acid, and fluorouracil. CA: Carbohydrate antigen; CEA: Carcinoembryonic antigen.

Figure 2 Effect of cetuximab + FOLFOX4 regimen on inflammatory indices in advanced gastric carcinoma patients receiving evidence-based care. A: The research group had a significantly reduced interleukin (IL)-2 Levels after treatment, which was lower compared with the pre-treatment levels and the control group; B: The research group had a significantly elevated IL-10 Levels after treatment, which was lower compared with the pre-treatment levels and the control group. ^aP < 0.05 and ^bP < 0.01, respectively. FOLFOX4 consists of oxaliplatin, folinic acid, and fluorouracil. IL: Interleukin.